Levey AS, Eckardt KU, Dorman NM, et al. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int 2020;97:1117–1129.
Conway BN, May ME. Mortality experience of a low-income population with young-onset diabetes. Diabetes Care 2012;35:542–548.
Gu HF. Genetic and epigenetic studies in diabetic kidney disease. Front Genet 2019;10:507.
Ram C, Jha AK, Ghosh A, et al. Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: preclinical evidences with therapeutic approaches. Eur J Pharmacol 2020;885:173503.
Brunskill NJ. C-peptide and diabetic kidney disease. J Intern Med 2017;281:41–51.
Ruiz-Ortega M, Rodrigues-Diez RR, Lavoz C, et al. Special issue “Diabetic nephropathy: diagnosis, prevention and treatment”. J Clin Med 2020;9:813.
Pan XW, Lin XL, Huang X, et al. The burden of diabetes-related chronic kidney disease in china from 1990 to 2019. Front Endocrinol 2022;13:892860.
Pacilli A, Viazzi F, Fioretto P, et al. Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: the AMD-Annals initiative. Diabetes Metab Res Rev 2017;33:e2873.
Song J, Ni J, Yin X. The genetic side of diabetic kidney disease: a review. Int Urol Nephrol 2022. Epub ahead of print
Vistisen D, Andersen GS, Hulman A, et al. A validated prediction model for end-stage kidney disease in type 1 diabetes. Diabetes Care 2021;44:901–907.
Lacava V, Pellicanò V, Ferrajolo C, et al. Novel avenues for treating diabetic nephropathy: new investigational drugs. Expert Opin Inv Drug 2017;26:445–462.
Alehaideb Z, Chin KC, Yao MC, et al. Predicting the content of anthraquinone bioactive in Rhei rhizome (Rheum officinale Baill.) with the concentration addition model. Saudi Pharm J 2019;27:25–32.
Mohammed A, Ibrahim MA, Tajuddeen N, et al. Antidiabetic potential of anthraquinones: a review. Phytother Res 2020;34:486–504.
Liu J, Chen Z, Zhang Y, et al. Rhein protects pancreatic β-cells from dynamin-related protein-1-mediated mitochondrial fission and cell apoptosis under hyperglycemia. Diabetes 2013;62:3927–3935.
Yu C, Qi D, Sun J, et al. Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-κ B activities. Sci Rep 2015;5:11822.
Zhang MZ, Wang S, Yang S, et al. Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice. Am J Physiol Renal Physiol 2012;302:F433–F438.
Cheng Y, Zhang H, Qu L, et al. Identification of rhein as the metabolite responsible for toxicity of rhubarb anthraquinones. Food Chem 2020;331:127363.
Gómez-Gaete C, Retamal M, Chávez C, et al. Development, characterization and in vitro evaluation of biodegradable rhein-loaded microparticles for treatment of osteoarthritis. Eur J Pharm Sci 2017;96:390–397.
Nair AR, Lakshman YD, Anand VSK, et al. Overview of extensively employed polymeric carriers in solid dispersion technology. AAPS Pharm Sci Tech 2020;21:309.
Shariatinia Z. Carboxymethyl chitosan: properties and biomedical applications. Int J Biol Macromol 2018;120:1406–1419.
Zuckerman JE, Davis ME. Targeting therapeutics to the glomerulus with nanoparticles. Adv Chronic Kidney D 2013;20:500–507.
Guo S, Guo X, Zhang H, et al. The effect of diacerein on type 2 diabetic mellitus: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. J Diabetes Res 2020;2020:2593792.
Hu C, Cong XD, Dai D, et al. Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue. Naunyn Schmiedebergs Arch Pharmacol 2011;383:309–319.
Hu G, Zhan YZ, Luo GL, et al. Rhein lysinate protects pancreas in type 2 diabetic mice. J Third Milit Med Univ (Chin) 2014;36:461–465.
Said SM, Nasr SH. Silent diabetic nephropathy. Kidney Int 2016;90:24–26.
Zhao JX, Wang SD, Li J, et al. Studies about specification of syndrome differentiation on different stages and efficacy evaluation proposal for diabetic kidney disease. World J Tradit Chin Med (Chin) 2017;12:1–4.
Huang W, Chen YY, Li ZQ, et al. Recent advances in the emerging therapeutic strategies for diabetic kidney diseases. Int J Mole Sci 2022;23:10882.
Alvarez G, Chrusch C, Hulme T, et al. Renal replacement therapy: a practical update. Can J Anaesth 2019;66:593–604.
Backholer K, Peeters A, Herman WH, et al. Diabetes prevention and treatment strategies. Diabetes Care 2013;36:2714–2719.
Kotsis V, Martinez F, Trakatelli C, et al. Impact of obesity in kidney diseases. Nutrients 2021;13:4482.
Jiang S, Quan DV, Sung JH, et al. Cigarette smoke inhalation aggravates diabetic kidney injury in rats. Toxicol Res 2019;8:964–971.
Monno I, Ogura Y, Xu J, et al. Exercise ameliorates diabetic kidney disease in type 2 diabetic fatty rats. Antioxidants 2021;10:1754.
Chen Y, Wang X, Jia Y, et al. Effect of a sodium restriction diet on albuminuria and blood pressure in diabetic kidney disease patients: a meta-analysis. Int Urol Nephrol 2022;54:1249–1260.
de Boer IH. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014;37:24–30.
Noguchi H, Kitada H, Kaku K, et al. Outcome of renal transplantation in patients with type 2 diabetic nephropathy: a single-center experience. Transplant Proc 2015;47:608–611.
Anders HJ, Huber TB, Isermann B, et al. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol 2018;14:361–377.
Mima A. A narrative review of diabetic kidney disease: previous and current evidence-based therapeutic approaches. Adv Ther 2022;39:3488–3500.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;337:644–657.
Su K, Yi B, Yao B, et al. Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis. Pharmacol Res 2020;156:104778.
Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. JAMA 2019;321:69.
Wang J, Xiang H, Lu Y, et al. New progress in drugs treatment of diabetic kidney disease. Biomed Pharmacother 2021;141:111918.
Moratal C, Laurain A, Naïmi M, et al. Regulation of monocytes/macrophages by the renin-angiotensin system in diabetic nephropathy: state of the art and results of a pilot study. Int J Mol Sci 2021;22:6009.
Kaku K, Chin R, Naito Y, et al. Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study. Expert Opin Drug Saf 2022;19:211–221.
Walley T, Winstanley P, Roberts D, et al. Adverse effects of captopril in hospital outpatients with hypertension. Postgrad Med J 1990;66:106–109.
Ayhanci A, Cengiz M, Mehtap Kutlu H, et al. Protective effects of ellagic acid in d-galactosamine-induced kidney damage in rats. Cytotechnology 2016;68:1763–1770.
Brenneman J, Hill J, Pullen S. Emerging therapeutics for the treatment of diabetic nephropathy. Bioorg Med Chem Lett 2016;26:4394–4402.
Chen CM, Zhang MM, Hu LM. Effect of rhein on the expression of PPAR γ and TGF-β 1 in renal cortex of obese diabetic rats. J Chin Med Mater (Chin) 2015;38:810–812.
Lin W, Li H, Yang Q, et al. Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis. Stem Cell Res Ther 2021;12:43.
Persson F, Frimodt-Møller M, Rossing P. Inflammation leads the way on the ROADMAP to diabetic kidney disease. Kidney Int Rep 2019;4:1362–1365.
Navarro-González JF, Mora-Fernández C, de Fuentes MM, et al. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011;7:327–340.
Donate-Correa J, Luis-Rodríguez D, Martín-Núñez E, et al. Inflammatory targets in diabetic nephropathy. J Clin Med 2020;9:458.
Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol 2020;16:206–222.
Wang X, Yao B, Wang Y, et al. Macrophage cyclooxygenase-2 protects against development of diabetic nephropathy. Diabetes 2017;66:494–504.
Torres Á, Muñoz K, Nahuelpán Y, et al. Intraglomerular monocyte/macrophage infiltration and macrophage-myofibroblast transition during diabetic nephropathy is regulated by the A2B adenosine receptor. Cells 2020;9:1051.
Bi F, Chen F, Li Y, et al. Klotho preservation by rhein promotes toll-like receptor 4 proteolysis and attenuates lipopolysaccharide-induced acute kidney injury. J Mol Med (Berl) 2018;96:915–927.
Panah F, Ghorbanihaghjo A, Argani H, et al. Ischemic acute kidney injury and klotho in renal transplantation. Clin Biochem 2018;55:3–8.
Maekawa Y, Ishikawa K, Yasuda O, et al. Klotho suppresses TNF-α-induced expression of adhesion molecules in the endothelium and attenuates NF-κ B activation. Endocrine 2009;35:341–346.
Lim SW, Shin YJ, Luo K, et al. Effect of Klotho on autophagy clearance in tacrolimus-induced renal injury. FASEB J 2018;33:2694–2706.
Smith ER. Untangling the thread of life spun by α Klotho. J Mol Med (Berl) 2018;96:857–859.
Ge H, Tang H, Liang Y, et al. Rhein attenuates inflammation through inhibition of NF-κ B and NALP3 inflammasome in vivo and in vitro. Drug Des Devel Ther 2017;11:1663–1671.
Gao Y, Chen X, Fang L, et al. Rhein exerts pro- and anti-inflammatory actions by targeting IKK β inhibition in LPS-activated macrophages. Free Radical Bio Med 2014;72:104–112.
Ye L, Chen T, Cao J, et al. Short hairpin RNA attenuates liver fibrosis b
留言 (0)